Periodic Reporting for period 1 - RESPILIQ (RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure)
Reporting period: 2024-05-01 to 2025-04-30
Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide, affecting millions of people with a high socioeconomic burden. The major challenge in the treatment of COPD patients is hypercapnia (too much CO2 in the blood). Standard treatment involves non-invasive ventilation (NIV) affecting the quality of life significantly. As a result, many patients with COPD continue to struggle with hypercapnia.
RESPILIQ™ (the liquid breath) is a novel therapeutic approach (medical device) that uses the intestine as an alternative gas exchange organ to eliminate CO2. This allows the lung to rest and avoid further damage by intensive ventilation therapies. We have developed a pilot plant and in our preclinical studies. we successfully demonstrated the safety and efficacy of RESPILIQ™. Our research and development aim to prolong the survival of the patients with COPD and, above all, improving their quality of life.
Current gold standard therapies for CO2 removal from the human body either focus on increasing the CO2 elimination via the lung by mechanical ventilation or involve extracorporeal systems that pass blood through a gas exchange membrane outside of the human body. RESPILIQ™ is the first medical product developed for capturing CO2 via the intestines, delivering a highly effective therapy in a significant less invasive way.